Journal Article

Results of phase I/II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor

E Stein

in European Heart Journal Supplements

Published on behalf of European Society of Cardiology

Volume 3, issue suppl_E, pages E11-E16
Published in print June 2001 | ISSN: 1520-765X
Published online June 2001 | e-ISSN: 1554-2815 | DOI: http://dx.doi.org/10.1016/S1520-765X(01)90107-5
Results of phase I/II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor

Show Summary Details

Preview

Phase I/II studies in patients with hypercholesterolaemia have explored the safety and efficacy of ezetimibe mono-therapy and co-administration with a statin. In an 8-week dose-ranging study, daily doses of 1–40 mg of ezetimibe reduced low-density lipoprotein cholesterol (LDL-C) levels in a fairly flat dose-dependent manner. A second dose-ranging study confirmed that optimal efficacy, of 19% reduction in LDL-C level at 12 weeks, was achieved with the 10-mg dose. A dose-regimen, or dose-scheduling, study of morning versus evening dosing produced similar reductions of LDL-C levels, showing that timing of dosing does not affect treatment response. Pooled efficacy results from these two monotherapy studies confirmed that ezetimibe 10 mg.day−1 significantly ([math]) reduced LDL-C levels by approximately 18%; ezetimibe also reduced triglyceride levels by approximately 5% and increased high-density lipoprotein cholesterol levels by approximately 3·5%. An additional study of 10 mg of ezetimibe co-administered with 10 mg of simvastatian showed that ezetimibe does not affect the pharmacokinetics of the statin and provides a 17% additive reduction in LDL-C levels compared with simvastatin monotherapy. Other studies with ezetimibe indicate minimal potential for drug interactions. Ongoing phase III trials are expected to confirm that ezetimibe, alone or in combination with a statin and as an adjunct to diet, provides consistent and predictable reductions in LDL-C level of 18%, with no new or worsened statin-related side-effects.

Keywords: Cholesterol absorption inhibitor; ezetimibe; hypercholesterolaemia; phase II studies; pharmacokinetic/pharmacodynamic; statins

Journal Article.  0 words. 

Subjects: Cardiovascular Medicine

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.